Medical cannabis provides an opportunity for cannabis exporters due to the state of legalisation and ability to export under international treaties and law.
Medical cannabis is legalised in most European countries, excluding France, which is undergoing trials.
This market is heavily regulated, due to it being a prescription medicine. Regulations and laws differ from country to country.
In many cases, medical cannabis is only available for certain conditions or circumstances.
Most commonly, it is prescribed for conditions such as epilepsy, chemotherapy side effects, and multiple sclerosis.
CBD is sold in most European markets. However, the legal context for these products is very ambiguous and still developing in a lot of markets.
CBD can be considered a food supplement, so there are regulations to consider in each market in this respect too.
The allowance threshold for THC (Tetrahydrocannabinol), the psychoactive compound found in cannabis, differs between countries as well.
Adult use cannabis remains illegal in many European markets.
However, there have been legal developments in several countries, namely legalisation in Germany, planned legalisation in the Czech Republic, and pilot programmes in Switzerland and the Netherlands.
The recreational space does not offer opportunities for exporters due to international treaties, however, increased liberalisation may impact consumer perceptions and uptake in the medical space.
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
